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Background/aim: In tuberculsosis (TB), miRNA has been used as a biomarker to distinguish between healthy individuals and
TB patients. The aim of this study was to investigate (i) the association of the miRNA and cytokine expression levels, the course of
tuberculosis infection, clinical forms and response to treatment, and (ii) the effects of genotypic features of bacteria on the course of
tuberculosis and the relationship between miRNA and cytokine expressions and bacterial genotypes.
Materials and methods: A total of 200 cases (100: culture positive active tuberculosis, 50: quantiferon positive latent tuberculosis
infection and 50: quantiferon negative healthy controls) were included in the study. For the tuberculosis group at the time of admission
and after treatment, for the latent tuberculosis infection and healthy control groups at the time of admission, miRNA and cytokine
expressions were determined. Genotyping of M.tuberculosis isolates was performed by spoligotyping method.
Results: While, in the comparison of miRNA expressions between the pretreatment patient group and the healthy control group,
there was a statistically significant decrease in the expression of miR-454-3p, miR-15a-5p, miR-590-5p, miR-381, and miR-449a in
the Pulmonary TB group, there was no significant change in miRNA expression in extrapulmonary TB patients. When the cytokine
expressions of the patient group and the healthy control group were compared before treatment, the expressions of all cytokines in the
patient group decreased. However, the only cytokine that showed a significantly lower expression was IL12A in PTB patients.
Conclusion: There is no significant relationship between the clinical course of the disease, cytokine and miRNA expression, and the
genotype of the bacteria.
Key words: Tuberculosis, latent tuberculosis infection, miRNA expression, cytokine, miRNA expression, spoligotyping

1. Introduction
It is estimated that approximately 1/3 of the world’s
population is latently infected with tuberculosis bacillus,
whereas active tuberculosis (TB) develops in approximately
10% of latent tuberculosis infection (LTBE) people.
According to the World Health Organization (WHO)
data, the number of new TB cases in 2017 was estimated as

10 million, including 5.8 million men, 3.2 million women,
and 1 million children. In 2017, nearly 1.3 million HIVnegative people died because of TB [1]. The incidence of
TB in Turkey has dropped 26/100 000 in 2005 to 16.9/100
000 in 2014 and 14.6/100 000 in 2017 [2–3]. In total, 12046
new TB cases, consisting of 66.1% pulmonary and 33.9%
extrapulmonary, were reported in Turkey in 2017 [3].
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Complex clinical manifestations such as latent
asymptomatic infection, active pulmonary and
extrapulmonary TB can be seen in TB patients; therefore,
it is essential to classify TB cases correctly in order to
choose the most appropriate treatment method [4]. There
is currently no biological indicator that can distinguish
LTBE and active TB [5, 6]. An ideal biomarker should
be a stable molecule and is expected to reach easily
detectable amounts in body fluids [6, 7]. The development
of diagnostic tests based on host biomarkers will help to
identify cases classified as microbiologically unverified TB
and LTBE cases appropriately [8–10].
MiRNAs bind to the mRNA, causing subsequent
inhibition of protein translation and/or degradation of
the mRNA, so they have an important role in regulating
protein synthesis by reducing the expression of target genes
[11]. It is known that each of the miRNAs can regulate the
expression of several mRNAs, and each of the mRNAs can
be targeted by several miRNAs [12]. The expression of host
miRNA during bacterial infections is not fully understood.
In TB, miRNA has been used as a biomarker in different
studies to distinguish between healthy individuals and TB
patients.
In this study, it was aimed to investigate (i) the
association of the mRNA and miRNA expression levels
that play role in regulation of inflammation-related genes
and the course of TB infection (latent TB/ active TB),
clinical forms (pulmonary TB/ extrapulmonary TB) and
response to treatment, and (ii) the effects of genotypic
features of bacteria on the course of tuberculosis and the
relationship between inflammation-related miRNA and
cytokine expressions and bacterial genotypes.
2. Materials and methods
2.1. Patients
A total of 100 adult new TB patients aged ≥ 18 years, 84
of whom were pulmonary tuberculosis (PTB) and 16
were extrapulmonary TB (EPTB), who applied to the Ege
University Medical Faculty Department of Chest Diseases,
Department of Infectious Diseases and Suat Seren
Training and Research Hospital Chest Diseases outpatient
and inpatient services were included in this study. Blood
samples were obtained from the patients for miRNA and
mRNA analysis at the time of initial admission and at the
end of treatment. In addition to clinical and radiological
findings, patients with M. tuberculosis complex growing in
at least one of their cultures was considered as an inclusion
criterion for TB patients. The presence of fever and weight
loss was accepted as constitutional symptoms, and patients
were evaluated in terms of constitutional symptoms,
hemoptysis, presence of acid-fast bacilli (AFB) in smear
and cavitary lesions on radiography.
2.2. Healthy and LTBE group
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Fifty healthy volunteers without any clinical and
radiological findings of TB, no contact history within the
past 2 months, and who were negative for QuantiFERONTB Gold In-Tube (QFT) test and 50 healthy LTBE
volunteers who were positive for the Quantiferon (QFT)
test were included in the study. One blood sample was
taken from the healthy and LTBE groups for miRNA and
mRNA analysis. The QFT test was carried out briefly by
the manufacturer of the kit as described below.
2.3. Microbiological examination
2.3.1. QuantiFERON-TB gold in-tube test (QIAGEN)
The QFT test was carried out in accordance with the
manufacturer’s recommendations 1. In brief, 1 mL of
venous blood collected from the patients was added into
the Nil Control, Mitogen Control and TB antigen tube in
the kit, and the tubes were incubated at 37 °C for 16–24 H.
After incubation, tubes were centrifuged at 3000 x g for 15
min to separate plasma. 50 µL conjugate in microplate wells
and 50 µL plasma samples (Nile, TB Antigen and Mitogen)
in suitable wells and incubated at room temperature for 2
h. After washing and drying, 100 µL of enzyme substrate
solution was added to the wells and incubated for 30 min
at room temperature, and the optical density of each well
was measured by reading in the ELISA reader. Optical
density values were analyzed using the QuantiFERON-TB
Gold Analysis Software. The results of the analysis were
evaluated as positive, negative, or indeterminate.
2.3.2. Microscopy and culture
From the patients included in the study, two samples were
taken for culture: the first one was taken at the time of
application and the second one at the 5th month.
Microscopy, culture, and sensitivity tests of the samples
were performed as described in the national/international
guidelines, and the recommendations of the manufacturers
of the kits were used during the procedures. BACTEC
MGIT 960 automated system (BD, USA) was used for
culture, and isolates that were found positive in MPT64
card test were identified as Mycobacterium tuberculosis
(MTC). Drug susceptibility tests of the isolates were
performed by the BACTEC MGIT 960 automated system
[13, 14].
2.3.3. Genotyping of MTC strains
A standard spoligotyping procedure was performed as
described by Kamerbeek et
al. [15]. All spacers in the direct repeat (DR) region
were amplified with PCR using DRa (biotin-labeled) and
DRb primers. The biotin-labeled amplified spacers were
hybridized with different spacer probes that covalently
bond to the membrane. The spacers hybridized on the
membrane were incubated with HRP-conjugate and
substrate. The membrane was treated with X-ray or
visualized by Fusion FX7 (Vilber Lourmat, France)
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chemiluminescence imaging systems to detect hybridized
spacers. The presence of a hybridized spacer was considered
as a positive signal, while the lack of spacer hybridization
was considered as a negative signal. The binary spoligotype
values obtained for each strain were entered into the
database given at http://www.pasteur-guadeloupe.fr/tb/
bd_myco.html, and the spoligo international type (SIT)
number and the family that it belongs to were determined.
2.4. miRNA expression analysis
Total RNA was isolated from the blood obtained from the
patient and control groups with the TRIzol Plus Isolation
kit. The quality and concentration of isolated RNA was
determined by the NanoDrop 1000 system (ThermoFisher
Scientific, Wilmington, DE, USA). Only RNA with 260/280
nm ratios of 1.8 to 2.0 was used for reverse transcription.
Total RNAs were converted to cDNA with TaqMan TM
miRNA Reverse Transcription Kit and stored until –80 °C
working. The expression of 83 miRNAs was determined
by Real Time RT-PCR (ABI 7500 fast system). RNU-48
and RNU-388 were used for normalization of microRNA
expression levels in quantitative RT-PCR assays. The list of
miRNAs examined in the study is attached.
2.5. Cytokine expression analysis
Total RNA was isolated from the blood obtained
from the patient and control groups with the TRIzol plus
isolation kit. The quality and concentration of isolated
RNA were determined by the NanoDrop 1000 system
(ThermoFisher Scientific, Wilmington, DE, USA). Total
RNAs were converted to cDNA with high-capacity cDNA
reverse transcription kit and stored until –80 °C working.
The expression of cytokine mRNAs was determined
by real time RT-PCR (ABI 7500 fast system). Cytokines
selected for expression analysis were CCL8, IL12A,
CXCL10, IL17A, IFNG, TNF, IL2RG, IL10, TNFRSF1A,
IL4, TNFRSF1B, IL6, and IL8.
2.6. Statistical analysis
∆/∆ Ct method was used for relative quantitation of
miRNA and mRNA expression results. After calculating
the Ct (threshold cycle) with the help of the device
software, the results were analyzed in miScript miRNA
PCR array data analysis web-based software package
(pcrdataanalysis.sabiosciences, 2018). After loading the
Ct values, the relative quantification and fold change
were automatically calculated by using the software ΔΔCt
method, and the log2 transformation was applied to the
results. Fold changes calculation from the uploaded raw
threshold cycle data were calculated by automatically webbased software. p values were calculated using student’s
t-test to compare the differences in miRNA expression fold
changes between each group. Fold expression changes of
± 2 times and p value <0.05 were considered statistically
significant.

3. Results
3.1. Patients and control groups
A total of 100 patients, 28 females and 72 males, between
the ages of 18 and 80, with an average age of 46.7 were
included in the study. Nighty-eight patients successfully
completed the treatment period. One patient with
Beijing spoligotype that was resistant to isoniazid and
streptomycin was cured in 18 months, and one patient
stopped his treatment at 4th month and then completed
the treatment later and was cured. While 84 of 100 MTC
strains isolated from patients were sensitive to all drugs, no
strain with multiple drug resistance was detected.
Of the 84 PTB patients included in the study, 49 were
positive for smear, 15 had hemoptysis, 55 had cavitary
lesions on chest radiography, and 48 had constitutional
symptoms. Cavitary lesions and smear positivity were
lower in patients with Haarlem family strains and
higher in patients with LAM7TUR and zoonotic strains.
Constitutional symptoms were detected at lower rates in
patients with LAM7TUR strains, while hemoptysis was
found at lower rates in patients with Haarlem, Beijing, and
zoonotic strains. Of the 16 EPTB patients included in the
study, 7 were positive for smear and 8 had constitutional
symptoms. The most common families, clinical and
demographic findings in PTB and EPTB cases are
summarized in Table 1 and Table 2. A total of 100 control
cases were included in the study: 50 QFT (+) LTBE within
the age range of 21–83, an average age of 57.4, and 50 QFT
(-) healthy controls within the age range of 19–72 and an
average age of 46.5.
3.2. miRNA and cytokine expressions according to
genotypes
The comparison of pretreatment and posttreatment
periods in patients showed a change only in the
expression of miR-590-5p. The patients infected with
LAM7TUR (Fold change: 2.53, p = 0.012) and zoonotic
strains (Fold change: 2.34, p = 0.007) showed statistically
significant higher miR-590-5p expression levels after the
treatment. In addition, when the control group and the
pretreatment patient group were compared with each
other, the expression levels of 5 miRNAs were found
to be significantly different (Table 3). When compared
to the control group, miR-21-5p expression levels were
found to be significantly higher (Fold change: 2.81, p =
0.011) in pretreatment patient group infected with Beijing
strains, higher miR-15b-5p expression (fold change: 2.34,
p = 0.037) in LAM7TUR strains and lower miR-590-5p
expression in other strains (fold change: –2.05, p = 0.038).
In the comparison of the healthy control group and the
pretreatment patient group, cytokine expressions (IL12A,
IL17A, IFNG, IL4, IL6, IL8, and IL10) were found to be
decreased by 2 times or more in all genotypes, which
was not statistically significant. In the comparison of the
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Table 1. The most frequent Mycobacterium tuberculosis complex families and clinical findings in PTB cases (n = 84).
Hemoptysis
n (%)

Cavity
n (%)

Const symptoms
n (%)

Gender
n (%)

Pre

Abs

Pre

Abs

Pos

Neg

Pre

Abs

M

F

T

5
(13)

33
(87)

26
(68)

12
(32)

23
(61)

15
(39)

21
(55)

17
(45)

33
(87)

5
(13)

48.4

Haarlem

0
(0)

11
(100)

4
(3)

7
(6)

5
(45)

6
(55)

7
(64)

4
(36)

7
(64)

4
(36)

45.2

LAM7
TUR

3
(43)

4
(57)

5
(71)

2
(29)

5
(71)

2
(29)

2
(29)

5
(71)

5
(71)

2
(29)

58.1

Zoonotic

0
(0)

5
(100)

4
(80)

1
(20)

4
(80)

1
(20)

3
(60)

2
(40)

4
(80)

1
(20)

37.6

Beijing

0
(0)

3
(100)

2
(67)

1
(33)

2
(67)

1
(33)

2
(67)

1
(33)

3
(100)

0
(0)

37.3

Others

7
(35)

13
(65)

14
(70)

6
(30)

10
(50)

10
(50)

13
(65)

7
(35)

15
(75)

5
(25)

37.8

Total

15
(18)

69
(82)

55
(65)

29
(35)

49
(58)

35
(42)

48
(57)

36
(43)

67
(80)

17
(20)

45.3

Family

Smear
n (%)

Ave
age

Pos: Positive, Neg: Negative, Pre: Present, Abs: Absent, M: Male, F: Female, Ave: Average, Const: Constitutional.
Table 2. The most frequent Mycobacterium tuberculosis complex families and
clinical findings in EPTB cases (n = 16).

Family

Smear

Constitutional symptoms

Positive

Negative

Present

Absent

T

3(60%)

2 (40%)

3 (60%)

2 (40%)

Zoonotic

3(100%)

0 (0%)

1 (33%)

2 (67%)

Others

3 (37%)

5 (63%)

4 (50%)

4 (50%)

Total

9 (56%)

7 (44%)

8(50%)

8 (50%)

pretreatment and posttreatment period, no statistically
significant change was found in cytokine expression in
any genotype and between genotypes. In the comparison
of pretreatment and posttreatment period, it was found
that IFNG / IL4 ratio increased 3.2 times in Beijing strains
and 1.1 times in LAM7TUR strains, whereas IFNG / IL4
ratio decreased in other genotypes. In the comparison of
the pretreatment patients and the control group, the rate
of IFNG/ IL4 increased 1.2 times in Beijing strains and
3.6 times in LAM7TUR strains, 5.4 times in the Haarlem
family, 5.7 times in the zoonotic strains, 8 times in the T
family, and 10 times in other families, respectively.
3.3. Comparison of miRNA and cytokine expressions of
patient group and healthy control group
While, in the comparison of miRNA expressions between
the pretreatment patient group and the healthy control
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group, there was a statistically significant decrease in
the expression of miR-454-3p, miR-15a-5p, miR-5905p, miR-381, and miR-449a in the PTB group, whereas
there was no significant change in miRNA expression
in EPTB patients (Table 3, Figure 1). When the cytokine
expressions of the patient group and the healthy control
group were compared before treatment, the expressions of
all cytokines in the patient group decreased. However, the
only cytokine that showed a significantly lower expression
was IL12A in PTB patients (Table 4).
3.4. Comparison of miRNA and cytokine expressions of
the patient group and LTBE group
When miRNA and cytokine mRNA expressions were
compared in the pretreatment group and LTBE group,
there were no significant expression levels of miRNA and
cytokine.
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Table 3. Comparison of miRNA expression levels between
pretreatment LTB and QF(-) group
miRNA

Fold Change *

p value *

miR-454-3p

-2.33

0.002

miR-15a-5p

-3.31

0.010

miR-590-5p

-2.21

0.001

miR-381

-2.82

0.030

miR-449a

-2.24

0.000

* Fold changes were calculated automatically miScript miRNA
PCR array data analysis web-based software package using raw
threshold cycle data and p values were calculated using student’s
t-test.

3.5. Comparison of miRNA and cytokine expressions
before and after treatment in the patient group
When the posttreatment and pretreatment periods were
compared, no significant change in the expression of
miRNA was detected. In addition, after treatment, over
2-fold decrease was detected in the expression levels of
CCL8, CXCL10, IL17A, IFNG, TNF, IL2RG, TNFRSF1A
and IL4 cytokines in EPTB cases (Table 5, Figure 2).
3.6. Comparison of miRNA and cytokine expressions of
healthy control and LTBE
Significant difference was not found between the LTBE
group and the healthy control group.
4. Discussion
In our study, when compared miRNA expressions between
the pretreatment patient group and the healthy control
group revealed, a significant decrease was noticeable in

the expressions of miR-454-3p, miR-15a-5p, miR-590-5p,
miR-381, and miR-449a in the PTB group, statistically.
However, no significant change was determined in miRNA expression in EPTB patients. Also, when the posttreatment and pretreatment periods and pretreatment group
and LTBE group were compared, significant change in the
expression of miRNA was not detected.
To date, many studies showed Beijing strains’ shortest latency and highest virulence features, while T, LAM,
and Haarlem strains’ more virulent than EAI strains and
other geographically restricted MTC strains [16–20]. Also,
no data are available regarding the virulence of zoonotic
TB strains. If the cavitary lesions and smear positivity are
considered as indicators of the severity and infectiousness
of the disease, the clinical course of TB disease caused by
Eurasia strains including potentially virulent LAM7TUR
strains and Beijing strains can not be distinguished from
other TB strains. Epidemiological studies on the effects
of MTC strains on disease outcomes have yielded highly
variable results. In some studies, no relationship has been
established between MTC strain and disease appearance,
while other studies have suggested that there is a relationship between line EAI and Beijing strains and EPTB, while
T, LAM, and Haarlem strains rarely cause EPTB [20–22].
In our study, although the number of EPTB cases was limited, no relation could be established between MTC strain
and clinical manifestation.
Our study is the first study that investigates miRNA
expression in MTC genotypes. In comparison of the
pretreatment and posttreatment patient group, miR-590b5p was found to be the only miRNA with varying expression
levels and was found to be upregulated in LAM7TUR and
zoonotic strains. In comparison of the control group and
the pretreatment patient group, miR-15b-5p and miR-21-

2

1

Fold change

0

-1

-2

-3

-4

miR-15a-5p

miR-381

miR-454-3p

miR-449a

miR-590-5p

Figure 1. Fold changes of miRNA expression levels between pretreatment
LTB and QF (-) groups.
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Table 4. Comparison of Mrna expression levels between
pretreatment LTB and QF(-) group.

Table 5. Comparison of mRNA expression levels in pre and
posttreatment EPTB patients.

mRNA

Fold Change*

p value *

mRNA

Fold Change *

p value *

IL12A

–13.10

0.044

CCL8

–5621.50

0.005

CXCL10

–162.23

0.001

IL17A

–4650.92

0.022

IFNG

–433.74

0.006

TNF

–1043.05

0.002

IL2RG

–45.53

0.027

TNFRSF1A

–100.97

0.008

IL4

–1551.91

0.001

* Fold changes were calculated automatically miScript miRNA
PCR array data analysis web-based software package using raw
threshold cycle data and p values were calculated using student’s
t-test.

5p were found to be upregulated in LAM7TUR and Beijing
strains, respectively. In addition, in comparison of the
control group and the pretreatment patient group, miR590-5p was found to be downregulated in tuberculosis
genotypes other than T, Haarlem, LAM7TUR, Beijing,
and zoonotic strains. miR-590-5p is significantly induced
by various viruses and attenuates the expressions of IFNs
and inflammatory cytokines, which means that it plays
an important role in immune regulation [23]. In a study
investigating miRNA signatures in patients with active
pulmonary tuberculosis patients, miR-590-5p was found to
be significantly different between healthy and pulmonary
tuberculosis patients [9]. Although there is no study on the
expression of miR-15b-5p in active tuberculosis, it has been
reported that miR-15b-5p is upregulated in diabetic foot
ulcers infected by Staphylococcus aureus concluding that
S. aureus induces miR-15b-5p, subsequently repressing
DNA repair and inflammatory response, which reveals a
previously unreported mechanism of inhibition of healing
in diabetic foot ulcers [24].
In our study, untreated TB patients infected with
Bejing strains showed significantly increased expression

* Fold changes were calculated automatically miScript miRNA
PCR array data analysis web-based software package using raw
threshold cycle data and p values were calculated using student’s
t-test.

levels of miR-21-5p compared to control group in contrast
to previously reported study, which showed significantly
reduced expression levels of miR-21-5p in the cured TB
patients compared with the untreated TB patients [25].
Decreased miR-21-5p level after anti-TB treatment might
be due to the downregulation of innate host defense after
anti-TB therapy [25]. The authors assumed that increased
miR-21-5p expression in untreated TB patients might
be due to the improved inflammation and antibacterial
status. The reduction of miR-21-5p expression after antiTB treatment might reflect the decreased inflammation
and attenuated status of the immune system [25]. Also,
Kleinsteuber et al. [26] found increased expression of miR21 after in vitro restimulation of CD4+ cells in TB patients.

Fold change (Log2)

0

-5

-10

-15

CCL8

IL17A

IL4

TNF

IFNG

CXCL10 TNFRSF1A IL2RG

Figure 2. Fold changes of mRNA expression levels in pre and posttreatment
EPTB patients.
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Although upregulated miR-590-5p reduced the
expression of IFNs and inflammatory cytokines in our
study, the expression of all inflammatory cytokines was
upregulated after the treatment, while miR-590-5p was
found to be downregulated. Also, the comparison of
patients and control groups showed a decrease in the
expression of all proinflammatory and antiinflammatory
cytokines, despite downregulated miR-590-5p. miR21-5p enhances M. tuberculosis survival and apoptosis
and attenuates the secretion of inflammatory cytokines,
including interleukin (IL)-1b, IL-6, and TNF-α in M.
tuberculosis-infected macrophages [27]. In our study,
upregulated miR-15b-5p and attenuated inflammatory
cytokines were detected. Upregulated miR-15b-5p leads
to an increase in the secretion of IFN-γ and TNF-α [28].
Although miR-15b-5p is upregulated in our study, IFN-γ
and TNF-α expression levels were found to be significantly
decreased.
Macrophages infected with “modern” strains were
found to produce significantly less proinflammatory (IL6) cytokines compared to those infected with “ancient”
strains. In addition, T, LAM and Haarlem strains that
lead to delayed and decreased pro-inflammatory immune
response have been shown to be more virulent than EAI
strains in guinea pigs. These findings support that ‘modern’
strains can progress to the disease faster and infect new
hosts, avoiding early recognition by the immune system
due to hypoinflammatory natural immune responses
[16, 21, 29]. In studies comparing cytokine levels of
modern strains, conflicting findings were obtained.
In some studies, it has been stated that Beijing strains
exhibit a lower proinflammatory phenotype compared
to T, LAM and Haarlem strains, while other studies have
reported that T, LAM, and Haarlem strains cause more
TNF expression than Beijing strains. On the other hand,
Krishnan et al. did not detect any difference between these
strains [30]. Coussens et al. [31] found that ethnic origin
plays an important role in different inflammatory profiles,
while the MTC genotype does not significantly contribute
to different immune responses in this patient population.
TB patients are characterized by decreased levels
of IFN-ɣ and increased levels of IL-10 compared with
the healthy controls [6–8, 32]. In improved TB patients,
IFN-γ expression increases, and IL4 mRNA expression
decreases. In contrast, accelerated IFN- γ production in
patients at diagnosis, compared to controls and treated
patients were reported in another study [33]. In our
study, it was observed that a decrease in the expression
of all proinflammatory and antiinflammatory cytokines
in the patient groups to the control. On the other hand,

pretreatment and posttreatment patient groups showed
an increase in the expression of all proinflammatory and
antiinflammatory cytokines.
As there was wide inter individual variation in
the kinetics of cytokine production, it is difficult to
recommend a single optimal time point for analysis of
IFN-γ production. IFN-γ production in active TB patients
needs to be carefully interpreted as the kinetics of cytokine
production differ between patients at different stages of
treatment [33].
Several research groups observed that a lower IFN-ɣ/
IL-4 mRNA ratio was associated with more severe disease
in TB patients, and this ratio was higher in healthy
control subjects [32, 34, 35]. Therefore, these observations
indicate that when IFN-ɣ/IL-4 mRNA levels are higher,
the individual is more likely to control M. tuberculosis
infection [36]. In contrast, in our study, it was found that
IFN-ɣ / IL4 ratio increased in pretreatment patients in
comparison to the pretreatment and posttreatment period.
These results show that increased “virulence” requires
more than just a delay in early proinflammatory response
and suggests that the course of M. tuberculosis infection
is caused by the complex interaction of host immune
response and bacterial factors [20]. There are currently no
reliable single surrogate markers for disease progression
or treatment response although combinations of known
markers have not been sufficiently evaluated. The first
challenge in this field is to find new markers for inclusion
into such predictive models, but an equally challenging
task will be the development of new detection methods
that will enable measurement of these markers on a
large scale in resource-poor settings [37]. In conclusion,
there is no significant relationship between the clinical
course of the disease, cytokine and miRNA expression,
and the genotypes of the bacteria. In addition, miRNA
and cytokine expression profiles specific to LAM7TUR
genotypes could not be detected.
1
QuantiFERON® TB Gold (QFT) ELISA [online].
Website:
http://www.quantiferon.com/wp-content/
uploads/2017/04/English_QFT_ELISA_R04_082016.pdf
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